Cellyan Biotechnology Co., Ltd SEC filings HKPD

Cellyan Biotechnology Co., Ltd has 67 filings in SEC EDGAR's recent list, going back to Mar 29, 2024. Its latest annual report, Form 20-F, was filed on Aug 7, 2026 for the period ended Mar 31, 2026. The most recent current report (Form 6-K) was filed on Oct 21, 2026. The company's fiscal year ends on March 31.

Cellyan Biotechnology Co., Ltd SEC filings
Form Description Filed Period
6-K Current report (foreign issuer) Oct 21, 2026 Oct 21, 2026
6-K Current report (foreign issuer) Sep 24, 2026 Sep 23, 2026
6-K Current report (foreign issuer) Sep 23, 2026 Sep 23, 2026
6-K Current report (foreign issuer) Sep 10, 2026 Sep 9, 2026
6-K Current report (foreign issuer) Jul 16, 2026 Jul 16, 2026
6-K Current report (foreign issuer) Mar 27, 2026 Mar 26, 2026
6-K Current report (foreign issuer) Mar 18, 2026 Sep 30, 2025
6-K Current report (foreign issuer) Jan 16, 2026 Jan 16, 2026
6-K Current report (foreign issuer) Dec 31, 2025 Dec 30, 2025
6-K Current report (foreign issuer) Dec 17, 2025 Dec 17, 2025
6-K Current report (foreign issuer) Nov 24, 2025 Nov 24, 2025
6-K Current report (foreign issuer) Nov 12, 2025 Nov 12, 2025
6-K Current report (foreign issuer) Oct 7, 2025 Oct 6, 2025
6-K Current report (foreign issuer) Sep 11, 2025 Sep 11, 2025
6-K Current report (foreign issuer) Mar 28, 2025 Mar 28, 2025
6-K Current report (foreign issuer) Jan 17, 2025 Jan 17, 2025

Showing 16 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Wholesale-Drugs, Proprietaries & Druggists' Sundries (SIC 5122)
Listed as
HKPD (Nasdaq)
Fiscal year ends
March 31
Incorporated in
Cayman Islands
Headquarters
Kowloon
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
2007702
Former names
Hong Kong Pharma Digital Technology Holdings Ltd (until Dec 17, 2025)

Other Wholesale-Drugs, Proprietaries & Druggists' Sundries companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.